Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans

• Compass Pathways outlined plans to file a rolling NDA for COMP360 psilocybin in treatment-resistant depression, targeting completion in Q4 2026.
• U.S. launch targeted for H1 2027, contingent on FDA clearance; Breakthrough Therapy designation cited alongside a Priority Review Voucher in TRD.
• Two Phase 3 trials, COMP005 and COMP006, met the primary endpoint on MADRS change at Week 6 with P<0.001.
• Company highlighted durability through 26 weeks with infrequent dosing; additional dosing described as deepening response in some patients.
• Commercial rollout planning centers on certified treatment sites, REMS readiness, specialty pharmacy or buy-and-bill distribution, payer engagement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.